Research programme: protein tyrosine phosphatase 1B inhibitors - Abbott Laboratories
Alternative Names: A 119505; A 220435; A 321842; protein tyrosine phosphatase 1B inhibitors research programme - Abbott LaboratoriesLatest Information Update: 18 Sep 2006
At a glance
- Originator Abbott Laboratories
- Class Antihyperglycaemics
- Mechanism of Action Protein tyrosine phosphatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 18 Sep 2006 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
- 20 Aug 2003 This programme is still in active development
- 31 Jul 2001 Preclinical development for Type-2 diabetes mellitus in USA (Unknown route)